Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-29

Contribution of RXRs to myeloid cell biology: from hematopoietic stem cells to osteoclastogenesis

Objective

Hematopoietic stem cells (HSCs) yield blood precursors devoted to unilineage differentiation and production of mature blood cells, including red blood cells, megakaryocytes, lymphocytes and myeloid cells. Precursors of the myeloid lineage differentiate into monocytes and granulocytes but at given stages of their maturity they can be also sources of multinucleated osteoclasts. Consequently, any altered myelopoiesis can be directly linked to deficiencies in osteclastogenesis and impaired bone homeostasis. Retinoic X receptors (RXRa, RXRb and RXRg) are members of the nuclear receptor family. They appear to contribute to hematopoiesis and osteoclastogenesis via their roles as heterodimeric partners of several nuclear receptors. Functionally the most important isotype is RXRa during morphogenesis. Since RXRs can function either as homodimers or heterodimers, it is unclear whether the effects of RXRs on hematopoiesis and osteoclastogenesis are coupled to RXR homodimers, heterodimers, or involve the regulation of parallel pathways. Additionally, in mouse models of RXRa deletion, a partial redundancy in RXRa, b and g functions can be also observed. In this context, the goal of the presented project is to characterize the role of RXRs in HSC differentiation and osteoclastogenesis. In this project we will work with a knockout mouse model in which both RXRa and RXRb are selectively ablated in the hematopoietic system. Using this model we will be able to characterize the in vivo effects of the conditional inhibition of RXRa and b in the murine hematopoietic system and we can clarify the contribution of each isoforms to myeloid cell differentiation and osteoclastogenesis. The results are anticipated to open new perspectives for developing stem cell based therapies for the treatment of bone-related diseases such as osteoporosis or rheumatoid arthritis, nowadays affecting hundreds of millions of people worldwide.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-PEOPLE-2009-RG
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MC-ERG - European Re-integration Grants (ERG)

Coordinator

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
EU contribution
€ 45 000,00
Address
CALLE MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
Spain

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0